FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2914776935> ?p ?o ?g. }

• W2914776935 endingPage "182" @default.
• W2914776935 startingPage "177" @default.
• W2914776935 abstract "Myalgia and arthralgia immune-related adverse events (irAEs) in patients treated with checkpoint inhibitors (CPIs) present a clinical challenge. We describe the clinical characteristics and treatment of myalgia and arthralgia irAEs in CPI-treated patients with genitourinary (GU) malignancies.Patients with GU malignancies who were treated with CPIs and developed myalgia and arthralgia irAEs that resulted in interruption or discontinuation of CPI therapy were reviewed. Patient-, disease-, and irAE-related data were collected and analyzed.Twenty-one patients were identified. Eighteen (86%) had renal cell carcinoma; 3 (14%) had urothelial carcinoma. The majority (71%) were male; the median age at diagnosis was 56 years (range, 36-78 years). CPI therapy included anti-programmed death-ligand 1 (29%), anti-programmed cell death protein 1 (48%), and combined programmed cell death protein 1/cytotoxic T-lymphocyte-associated protein 4 antibodies (24%). The median time from CPI initiation to myalgia and arthralgia irAE was 5.1 months (range, 0.23-50.5 months). All patients were treated with prednisone with a median initial dose of 40 mg/d (range, 10-90 mg/d) for a median duration of 64 weeks (range, 3-242 weeks). Treatment with methotrexate (14%), infliximab (14%), tocilizumab (10%), gabapentin (10%), and etanercept (5%) was also required in some patients. Six (29%) patients restarted CPI therapy following symptom improvement, 3 (15%) switched to a subsequent therapy, and 12 (55%) patients had an ongoing sustained response to therapy (median, 14.5 months; range, 3-55 months) despite no subsequent anti-cancer therapy.Myalgia and arthralgia irAEs in CPI-treated patients with GU malignancies vary in timing of presentation, severity, and treatment. Multidisciplinary teams that include a rheumatologist are critical for optimal management. Durable response to CPIs can be maintained even after therapy discontinuation." @default.
• W2914776935 created "2019-02-21" @default.
• W2914776935 creator A5002681805 @default.
• W2914776935 creator A5004856138 @default.
• W2914776935 creator A5006332537 @default.
• W2914776935 creator A5008174951 @default.
• W2914776935 creator A5025529463 @default.
• W2914776935 creator A5026717218 @default.
• W2914776935 creator A5031016267 @default.
• W2914776935 creator A5033533727 @default.
• W2914776935 creator A5039745684 @default.
• W2914776935 creator A5041898186 @default.
• W2914776935 creator A5056587248 @default.
• W2914776935 creator A5070884694 @default.
• W2914776935 date "2019-06-01" @default.
• W2914776935 modified "2023-10-05" @default.
• W2914776935 title "Myalgia and Arthralgia Immune-related Adverse Events (irAEs) in Patients With Genitourinary Malignancies Treated With Immune Checkpoint Inhibitors" @default.
• W2914776935 cites W1585093095 @default.
• W2914776935 cites W1916602633 @default.
• W2914776935 cites W2085247907 @default.
• W2914776935 cites W2132916434 @default.
• W2914776935 cites W2179179825 @default.
• W2914776935 cites W2222086386 @default.
• W2914776935 cites W2275606382 @default.
• W2914776935 cites W2288531107 @default.
• W2914776935 cites W2305396859 @default.
• W2914776935 cites W2441690768 @default.
• W2914776935 cites W2559804019 @default.
• W2914776935 cites W2565782504 @default.
• W2914776935 cites W2566809924 @default.
• W2914776935 cites W2582671354 @default.
• W2914776935 cites W2588916311 @default.
• W2914776935 cites W2601055810 @default.
• W2914776935 cites W2606604537 @default.
• W2914776935 cites W2736166064 @default.
• W2914776935 cites W2745126191 @default.
• W2914776935 cites W2745624257 @default.
• W2914776935 cites W2746991247 @default.
• W2914776935 cites W2759963646 @default.
• W2914776935 cites W2765536375 @default.
• W2914776935 cites W2767110068 @default.
• W2914776935 cites W2768429453 @default.
• W2914776935 cites W2770788500 @default.
• W2914776935 cites W2771737095 @default.
• W2914776935 cites W2785613599 @default.
• W2914776935 cites W2786816161 @default.
• W2914776935 cites W2792937256 @default.
• W2914776935 cites W2793937731 @default.
• W2914776935 cites W2809615201 @default.
• W2914776935 doi "https://doi.org/10.1016/j.clgc.2019.01.021" @default.
• W2914776935 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30824360" @default.
• W2914776935 hasPublicationYear "2019" @default.
• W2914776935 type Work @default.
• W2914776935 sameAs 2914776935 @default.
• W2914776935 citedByCount "10" @default.
• W2914776935 countsByYear W29147769352020 @default.
• W2914776935 countsByYear W29147769352021 @default.
• W2914776935 countsByYear W29147769352022 @default.
• W2914776935 countsByYear W29147769352023 @default.
• W2914776935 crossrefType "journal-article" @default.
• W2914776935 hasAuthorship W2914776935A5002681805 @default.
• W2914776935 hasAuthorship W2914776935A5004856138 @default.
• W2914776935 hasAuthorship W2914776935A5006332537 @default.
• W2914776935 hasAuthorship W2914776935A5008174951 @default.
• W2914776935 hasAuthorship W2914776935A5025529463 @default.
• W2914776935 hasAuthorship W2914776935A5026717218 @default.
• W2914776935 hasAuthorship W2914776935A5031016267 @default.
• W2914776935 hasAuthorship W2914776935A5033533727 @default.
• W2914776935 hasAuthorship W2914776935A5039745684 @default.
• W2914776935 hasAuthorship W2914776935A5041898186 @default.
• W2914776935 hasAuthorship W2914776935A5056587248 @default.
• W2914776935 hasAuthorship W2914776935A5070884694 @default.
• W2914776935 hasConcept C126322002 @default.
• W2914776935 hasConcept C141071460 @default.
• W2914776935 hasConcept C197934379 @default.
• W2914776935 hasConcept C2778616394 @default.
• W2914776935 hasConcept C71924100 @default.
• W2914776935 hasConceptScore W2914776935C126322002 @default.
• W2914776935 hasConceptScore W2914776935C141071460 @default.
• W2914776935 hasConceptScore W2914776935C197934379 @default.
• W2914776935 hasConceptScore W2914776935C2778616394 @default.
• W2914776935 hasConceptScore W2914776935C71924100 @default.
• W2914776935 hasIssue "3" @default.
• W2914776935 hasLocation W29147769351 @default.
• W2914776935 hasLocation W29147769352 @default.
• W2914776935 hasOpenAccess W2914776935 @default.
• W2914776935 hasPrimaryLocation W29147769351 @default.
• W2914776935 hasRelatedWork W1586374228 @default.
• W2914776935 hasRelatedWork W2003938723 @default.
• W2914776935 hasRelatedWork W2045240138 @default.
• W2914776935 hasRelatedWork W2047967234 @default.
• W2914776935 hasRelatedWork W2118496982 @default.
• W2914776935 hasRelatedWork W2364998975 @default.
• W2914776935 hasRelatedWork W2369162477 @default.
• W2914776935 hasRelatedWork W2439875401 @default.
• W2914776935 hasRelatedWork W4238867864 @default.
• W2914776935 hasRelatedWork W2525756941 @default.
• W2914776935 hasVolume "17" @default.

• next